Dr. John Cush RheumNow
6 years 4 months ago
Adaptive clinical trial design advocated for drug development for the coronavirus #COVID-19 https://t.co/jcEdlFQtXQ
Dr. John Cush RheumNow
6 years 4 months ago
Grand News and much Deserved. Congrats Professor Shanmugam!! https://t.co/jUjEv9dQuM
Dr. Janet Woodcock DrWoodcockFDA
6 years 4 months ago
We are prioritizing the review of new ANDAs for drugs in shortage, and we recently approved a generic application for hydroxychloroquine to increase availability for patients who depend on this drug. https://t.co/eKqXlpRRQl
Dr. John Cush RheumNow
6 years 4 months ago
Please believe that the Coronavirus is not a hoax, COVID-19 is not a conspiracy. Your doubts, ideology and slick videos cant change nearly 100,000 Americans dying from COVID in 3 short months. Please be vigilant with Distance, washing and masks
Mike Putman EBRheum
6 years 4 months ago
FWIW, the Mahevas observational data and Tang et al RCT of 150 pts just published together in @bmj_latest
1. Read both as preprints, nice to see them in a respected peer reviewed journal
2. Neither support a benefit from HCQ in COVID-19
Both PDFs at https://t.co/Mbrq7bFHk0 https://t.co/rTpLnhGnkf
Dr. John Cush RheumNow
6 years 4 months ago
Study of 140 SLE pts shows 45–50% w/ IFN-I gene expression; all correlated w/ active skin & 2/6 w/ arthritis. IFN-induced Mx1 protein correlated with IFN-I score (P<0.0001); 25% showed high PMN expression assoc w/ fever, serositis, low WBC, steroid use. https://t.co/a3Fp3qdbkG
Dr. John Cush RheumNow
6 years 4 months ago
Secukinumab shown to work in 9/15 (67%) of refractory Behçet’s patients (mucosal and articular dz) by 3 mos - Retrospective study looked a complete or partial responders. #s increased to 86.7% at 6 months. Doses: either 150 or 300 mg qmonth https://t.co/a3Fp3qdbkG
Anakinra was studied in 29 COVID(+) patients with respiratory distress and high inflammatory markers (CRP or ferritin) and compared to non-anakinra patients, those on anakinra had better survival (90% vs. 56% ;p=0·009) and greater improvements in CRP and pulmonary function (72% vs 50%) compared to controls at day 21.
Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory arthropathy.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Dr. John Cush RheumNow
6 years 5 months ago
FDA has approved OTC availability of Voltaren Gel - now called Voltaren Arthritis Pain: a topical NSAID, 1st approved by FDA in 2007. Indicated for the pain of osteoarthritis - It has not been effective in strains, sprains, bruises, sports injuries https://t.co/Tla75Bn4H0
The latest hazardous spinoff to the coronavirus infection is an inflammatory, Kawasaki-like syndrome unique to children or adolescents with COVID-19. Sporadic reports from around the globe of this severe pediatric COVID syndrome have littered the news with brief mentions and little detail.
Dr. John Cush RheumNow
6 years 5 months ago
BCG & COVID: 1) Israeli study shows BCG vaccination during childhood had no protective effect on getting COVID-19 infection later. 2) Bladder cancer pts on BCG therapy who get COVID infection, can safely take IL-6 or IL-1 inhibitors, Just not TNF inhib. https://t.co/TlOj6b8Taf
As data continue to emerge about a multi-system inflammatory disorder in children apparently connected to COVID-19, evidence is growing that this is not your typical Kawasaki disease.
